Suzhou city, Jiangsu Province-based biotech firm CureGenetics Co., Ltd has raised a US$17 million series A round led by Qiming Venture Partners.
CMB International Capital Corporation Ltd, a wholly-owned subsidiary of China Merchants Bank, has led a RMB410 million (US$65 million) series C round in Beijing Biocytogen Co., Ltd., a gene targeted animal model and service supplier.
Shanghai-based biotechnology company Harbour BioMed, backed by Chinese investment firms Advantech Capital and Legend Capital, has acquired Netherlands-headquartered firm Harbour Antibodies BV to create a global oncology-focused biotechnology company.
iCarbonX, an artificial intelligence-enabled health data mining start-up backed by Tencent Holdings Ltd. and other investors, has acquired an Israeli image understanding firm Imagu Vision Technologies for an undisclosed amount, the company announced today.
A U.S. investor has challenged a management buyout proposal to take NASDAQ-listed Sinovac Biotech Ltd. private, saying the management and insiders made the bid one business day after the company received approval to produce a groundbreaking vaccine in China.
Tencent Holdings Ltd. has led a RMB1 billion (US$155 million) series A funding round in artificial intelligence-enabled health data mining start-up iCarbonX, according to the company’s founder quoted by Chinese media.
Suzhou city, Jiangsu province-based MabSpace Biosciences, a start-up focused on developing antibody therapeutics for cancer treatment, has completed US$15 million series A round of financing from Lilly Asia Venture.
Sacramento, California-based cancer screening biotech firm Anpac Bio-Medical Science Co., Ltd. has completed series A round of funding from Shanghai Zhangjiang Science & Technology Investment Corporation, according to a company announcement. The round is worth several million U.S. dollars, says the statement.
Guangzhou-based cancer diagnostic start-up Burning Rock Biotech has completed RMB150 million (US$23 million) series A+ round of funding from Lyfe Capital, Sequoia Capital and Legend Star, according to a company announcement. The company says it will use the proceeds on its research and development efforts, as well as developing new products to meet patient demand.